Biodexa Pharmaceuticals (STU:5MP2) Total Current Assets: €14.23 Mil (As of Dec. 2025)

What is Biodexa Pharmaceuticals Total Current Assets?

Biodexa Pharmaceuticals STU:5MP2 10 Total Current Assets is €14.23 Mil as of Dec. 2025. GuruFocus rates STU:5MP2 with a GF Score™ of 10/100 and a GF Value™ of €95,593.41.

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Biodexa Pharmaceuticals's total current assets for the quarter that ended in Dec. 2025 was €14.23 Mil.

Biodexa Pharmaceuticals (STU:5MP2) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Biodexa Pharmaceuticals's Liquidation Value for the quarter that ended in Dec. 2025 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	9.756	-	7.744	+	0.75 * 0.04	+	0.5 * 0
=	2.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biodexa Pharmaceuticals Total Current Assets Related Terms

Biodexa Pharmaceuticals Total Current Assets Historical Data

* Premium members only.

The historical data trend for Biodexa Pharmaceuticals's Total Current Assets can be seen below:

Biodexa Pharmaceuticals Total Current Assets Chart

Biodexa Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Current Assets

Get a 7-Day Free Trial

13.84

5.39

8.16

10.64

14.23

Biodexa Pharmaceuticals Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
Total Current Assets	Get a 7-Day Free Trial															8.16	8.89	10.64	10.58	14.23

10GF Score

Biodexa Pharmaceuticals PLC STU:5MP2

Total Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Biodexa Pharmaceuticals Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Biodexa Pharmaceuticals's Total Current Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	9.756	+	0.254	+	0	+	4.215
	=	14.23

Biodexa Pharmaceuticals's Total Current Assets for the quarter that ended in Dec. 2025 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	9.756	+	0.254	+	0	+	4.215
	=	14.23

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Frequently Asked Questions Learn more about Total Current Assets →

What does a Total Current Assets of €14.23 Mil mean?

Biodexa Pharmaceuticals (STU:5MP2) has a Total Current Assets of €14.23 Mil as of Dec. 2025. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Biodexa Pharmaceuticals and its competitors.

Is Biodexa Pharmaceuticals' Total Current Assets too high?

Biodexa Pharmaceuticals' current Total Current Assets is €14.23 Mil. Overall, Biodexa Pharmaceuticals has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.

How does Biodexa Pharmaceuticals' Total Current Assets compare to CASIF and OGEN?

Biodexa Pharmaceuticals' Total Current Assets of €14.23 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Current Assets for a Biotechnology company?

A good Total Current Assets depends on the Biotechnology industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Current Assets mean?

A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Biodexa Pharmaceuticals and its competitors. Biodexa Pharmaceuticals's current Total Current Assets is €14.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Biodexa Pharmaceuticals stock overvalued right now?

Biodexa Pharmaceuticals (STU:5MP2) has a current Total Current Assets of €14.23 Mil. The stock's GF Value™ is €95,593.41, compared to a current price of €110,400.00 — trading 15.5% above its estimated fair value. The current Total Current Assets is €14.23 Mil. Biodexa Pharmaceuticals' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Current Assets calculated?

Total Current Assets is calculated from a company's financial statements. For Biodexa Pharmaceuticals (STU:5MP2), the current Total Current Assets is €14.23 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biodexa Pharmaceuticals (STU:5MP2) Overvalued in 2026?

Based on GuruFocus' analysis, Biodexa Pharmaceuticals stock appears to be overvalued. The current stock price of €110,400.00 is trading 15.5% above its estimated GF Value™ of €95,593.41.

Key valuation signals for STU:5MP2:

Total Current Assets: €14.23 Mil
GF Value™: €95,593.41 vs. price of €110,400.00 (15.5% above fair value)
GF Score™: 10/100

No single metric tells the full story. See the STU:5MP2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biodexa Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies CASIF OGEN ELOX CPMV VBIO JAGX BBLG PKTX SLXN HEPA VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges BDRX:USA

Address 1 Caspian Point, Caspian Way, Cardiff, GBR, CF10 4DQ

Website https://www.biodexapharma.com

Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.

10GF Score

Get the complete analysis for STU:5MP2

Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€110,400.00

Price

€95,593.41

GF Value

View STU:5MP2 Analysis

See Total Current Assets data for all stocks →